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The present study was aimed to formulate and characterized chewable tablets of Paracetamol and 
Metoclopramide hydrochloride. Paracetamol and Metoclopramide hydrochloride is an oral fixed dose 
combination for the preparation of chewable tablets used to treat the symptoms of migraine as it comply with 
physicochemical properties require to improve the effectiveness of therapeutic agent, better bioavailability, 
improved patient acceptance (especially pediatrics) through pleasant taste, patient convenience; need no 
water for swallowing, fasten the absorption of drug and for rapid onset of action. The investigation was 
carried out to study the effect of different proportion of Avicel 101, Avicel 102 and moringa gum, which are 
superdisintegrating agents. The chewable tablets of Paracetamol and Metoclopramide hydrochloride were 
prepared by wet granulation method. Several physicochemical parameters like thickness, diameter, hardness, 
%weight variation, %loss in weight, drug content, disintegration time, in vitro dissolution studies, kinetics of 
drug release and stability studies for all the formulations were studied and were found within the acceptance 
limits. Formulation F7 (containing moringa gum 1%) showed the best cumulative drug release and 
disintegration time of 56 secs. 
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INTRODUCTION 
Administration of drugs through oral route is the most 
common and the easiest way to administer a drug. 
However, pediatric, geriatric and bedridden patient 
shows inconvenience swallowing conventional tablets 
or capsules due to difficulties in swallowing with lesser 
amounts of water with the medication, unable to tolerate 
the taste of many drugs when formulated as liquid 
dosage forms, resulting in poor patient compliance. The 
rationalized approach in case of medication leads to the 
development of chewable tablets. The advantages of 
chewable tablet include palatability, stability, precise 
dosing, portability and ease of dosing.[1] 
Chewable tablets have been designed so that they may 
be chewed in the mouth producing a pleasant tasting 
residue in the oral cavity that is easily swallowed and 
does not leave a bitter a unpleasant taste. Chewable 
tablets are the dosage forms, which are required to be 
broken and chewed in between the teeth before 
ingestion. These tablets are given to the children who 
have difficulty in swallowing and to the adults who 
dislike swallowing of drugs. Successfully tablet 
formulation development involves the careful selection 
of ingredients in order to manufacture a robust solid 
dosage form. Choosing the appropriate excipients to 
perform a specific function in a tablet formulation, such 
as disintegration or lubrication can be critical to 
achieving acceptable manufacturing performance. 
Sweeteners, both naturally occurring and synthetic, are 
one type of functional excipients commonly used in 
chewable tablet formulations to mask unpleasant tastes 
and facilitate pediatric dosing. 
Paracetamol and Metoclopramide hydrochloride is an 
oral fixed dose combination for the preparation of 
chewable tablets used to treat the symptoms of migraine 
as it comply with physicochemical properties require to 
improve the effectiveness of therapeutic agent, better 
bioavailability, improved patient acceptance (especially 
pediatrics) through pleasant taste, patient convenience; 
need no water for swallowing, fasten the absorption of 
drug and for rapid onset of action.[2] 
 
MATERIAL AND METHODS 
Metoclopramide hydrochloride, moringa gum, 
tartrazine, aspartame and vanilla flavor were purchased 
from Balaji drug, Gujrat,lactose, maize starch, citric 
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acid, sodium starch glycolate, magnesium stearate and 
talc were purchased from Central Drug House (P) Ltd. 
New Delhi, Paracetamol, Avicel 101 and Avicel 102 
were purchased from Sanjay Biological Museum, 
Amritsar and mannitol was purchased from Rankem, 
New Delhi. 
 
Preparation of chewable tablets containing 
Paracetamol and Metoclopramide hydrochloride: 
Chewable tablets containing 325 mg Paracetamol and 
5mg Metoclopramide hydrochloride were prepared with 
a total weight of 500 mg by wet granulation method of 
different homogeneous blends containing Avicel 101, 
Avicel 102 and moringa gum in different ratios 
individually in order to achieve the desire drug release 
profile. Drug and other excepients were sieved and 
mixed in a pestle and mortar. Maize starch and 
tartrazine (coloring agent) were dissolved in purified 
water to get a starch paste. Drug mix was added to 
starch paste and obtained wet mass, which was sieved 
form # 10 mesh sieve.  The obtained granules were 
dried in oven.  After drying the granules were passed 
through # 16 mesh sieve. Then added magnesium 
stearate and talc as lubricant and glident and thoroughly 
blended for 3 mins. The tablets were compressed using 
rotary punching machine using 11 mm punch. 
Compression force of machine was adjusted to obtain 
the hardness for each formulation.[3-4] 
Table:1 Formulation composition of chewable tablets containing Paracetamol & Metoclopramide hydrochloride 
Ingredients Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Paracetamol 325 325 325 325 325 325 325 325 325 
Metoclopramide hydrochloride 5 5 5 5 5 5 5 5 5 
Avicel 101 5 10 15 --- --- --- --- --- --- 
Avicel 102 --- --- --- 5 10 15 --- --- --- 
Moringa gum --- --- --- --- --- --- 5 10 15 
Lactose 75 70 65 75 70 65 75 70 65 
Mannitol 50 50 50 50 50 50 50 50 50 
Maize starch 15 15 15 15 15 15 15 15 15 
Citric acid 2 2 2 2 2 2 2 2 2 
Sodium starch glycolate 3 3 3 3 3 3 3 3 3 
Tartrazine 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Aspartame 10 10 10 10 10 10 10 10 10 
Vanilla flavour 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Magnesium stearate 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 
Purified water q.s q.s q.s q.s q.s q.s q.s q.s q.s 
 
Evaluation of chewable tablets containing 
Paracetamol and Metoclopramide hydrochloride: 
Pre-Compression Parameters 
[5]
 
Angle of repose 
In order to determine the flow property, the angle of 
repose was determined using the standard procedure. It 
is the maximum angle that can be obtained between the 
free standing surface of the powder heap and the 
horizontal plane.θ = tan−1
h
r
 
Determination of bulk density and tapped density 
A quantity of 5gm of the powder (W) from each 
formula was introduced into a 25 ml measuring 
cylinder. After the initial volume was observed, the 
cylinder was allowed to fall under its own weight onto a 
hard surface from the height of 2.5 cm at 2 sec intervals. 
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The tapping was continued until no further change in 
volume was noted. The bulk density, and tapped density 
were calculated using the following formulae - 
Bulk density = W / Vₒ Tapped density = W / Vf 
Where, W = weight of the powder, Vo = Initial volume, 
Vf = Final volume 
Compressibility index (Carr’s index) 
It was identified using the formula, 
C.I = 100 (V0 – Vf) / V 
Hauser’s Ratio 
It indicates the flow properties of the powder and is 
measured by the ratio of tapped density to the bulk 
density. 
Hauser’s Ratio = (W / Vf) / (W / V0) 
Where, W / Vf= Tapped density, W / V0 =Bulk density 
 
Post compression parameters:
[5--7]
 
 Shape of Tablets 
The Compressed tablets were examined under the 
magnifying lens for the shape of the tablet. 
Tablet dimensions 
Thickness and diameter were measured using a 
calliberated vernier caliper. Five tablets of each 
formulation were taken randomly and thickness was 
measured individually. 
Hardness 
Hardness indicates the ability of a tablet to withstand 
mechanical shocks while handling. The hardness of the 
tablet was determined using Monsanto hardness tester. 
It is expressed in kg/cm2. Five tablets were randomly 
picked and hardness of the tablet was determined. 
Friability Test 
The friability of tablets was determined using Roche 
friabilator. It is expressed in percentage (%). Twenty 
tablets were initially weighed (w0 initial) and transferred 
into friabilator was operated at 25rpm for 4 mins or run 
up to 100 revolutions. The tablets were weighed (w). 
The friability was then calculated by 
Friability = 100 (1-w/w0) 
Weight variation test 
Twenty tablets were selected at random and the average 
weight was determined. 
% Maximum positive deviation = (WH –A/ A) x 100 
% Minimum negative deviation = (A-WL/ A) x 100 
Where, WH = Highest weight in mg, WL=Lowest 
weight in mg, A= Average weight of tablet. 
Drug content estimation 
Five tablets were weighed individually and powdered. 
The powder equivalent to average weight of the tablet 
was weighed and drug was extracted in 0.1(N) HCl pH 
1.2, the drug content was determined measuring the 
absorbance at 249 nm and 310 nm after suitable dilution 
using UV visible spectrophotometer.1 
Disintegration test 
Disintegration test was carried out by using 
disintegration test apparatus. One tablet is placed in 
each tube, and the basket rack was positioned in a 1 ltr 
beaker of water, at 37°C ±2°C. A standard motor-driven 
device is used to move the basket assembly containing 
the tablets up and down through a distance of 5 to 6 cm 
at a frequency of 28 to 32 cycles per mins. The time 
taken for the tablet to disintegrate completely was 
noted.[7] 
In vitro drug release study 
In vitro drug release studies were performed to provide 
the amount of drug that is released at a definite time 
period. In these release studies for all formulations were 
carried out using tablet dissolution USP type II (paddle 
method). The dissolution media used was 0.1(N) HCl, 
pH 1.2 maintained at 37±0.50C and rotated 50 rpm. 
Aliquots were withdrawn at different time intervals and 
the same volume of fresh medium was replaced to 
maintain sink conditions. The samples were analysed 
against 0.1(N) HCl pH 1.2 as blank at λ max 249 nm 
and 310 nm using UV spectrophotometer.[8] 
 
RESULTS & DISCUSSION  
The diameter of all formulations ranged between 
6.20±0.05 to 6.80±0.05 mm and thickness was in the 
range of 1.60±0.03 to 2.00±0.32 mm. All the batches 
showed hardness in the range 3.75±0.42 to 4.64±0.64 
Kg/cm2. The friability was found to be below 1% 
ensuring that all the formulations were mechanically 
stable. Uniformity of weight and drug content was 
evaluated usually by weight variation and content 
uniformity test. The variations in weight were within the 
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range of -0.143±0.31 to 0.654±1.32% complying with 
Pharmacopoeia specifications (±7.5 %). The range of 
drug content for Paracetamol was 95.385±0.006 to 
98.256±0.005% and for Metoclopramide hydrochloride 
was 95.319±0.020 to 99.574±0.032% for all 
formulations. For all formulations disintegration time 
was in the range of 56±0.07 to 156±0.01 secs. The 
results were shown in Table No-5 to 6.  
 
Table 2: Pre-formulation parameter of Paracetamol 
Parameters Inference 
Appearance White or almost white 
Melting point 169±1.150C 
Solubility In water Partially Soluble 
In methanol Freely Soluble 
In Hcl Spraingly Soluble 
Flow 
properties 
Angle of repose 25.25±0.02 
Bulk density 0.5±0.02 gm/cc 
Tapped density 0.66±0.02 gm/cc 
Carr’s index 24.24±0.05 
Hausner’s ratio 1.32±0.01 
Assay 98.4% 
 
All the 9 formulations of prepared chewable tablets of 
Paracetamol and Metoclopramide hydrochloride were 
subjected to in vitro release studies. The results 
obtaining in vitro release studies were plotted in 
different model of data treatment. The release data 
obtained for formulations F1 to F9 were showed in 
Figure No-1 to 2. In the present study Paracetamol and 
Metoclopramide hydrochloride chewable tablet by wet 
granulation method using polymers like Avicel 101, 
Avicel 102 and moringa gum was developed. 
Formulation F7 containing Moringa gum 5% showed 
best cumulative drug release and disintegration time of 
56 secs, emerging as best formulation.  
 
Table 3: Pre-formulation parameter of Metoclopramide 
hydrochloride 
 
Parameters Inference 
Appearance Ligh yellowish 
Melting point 183±1.10°C 
Solubility In Acetone Soluble 
In methanol Partially Soluble 
In Hcl Soluble 
Flow 
properties 
Angle of repose 27.85±0.05 
Bulk density 0.45±0.02 gm/cc 
Tapped density 0.62±0.04 gm/cc 
Carr’s index 23.20±0.03 
Hausner’s ratio 1.25±0.03 
Assay 99.5% 
 
 
 
 
 
 
Table 4: Flow properties of granules of formulations F1-F9 
Formulation 
Code 
Bulk density
*
 
(gm/cm
3
)
 
Tap density
* 
   (gm/cm
3
) 
Carr’ index* 
       (%) 
Hausner’s  
    ratio
* 
Angle of 
repose
* ( θ ) 
F1 0.50±0.03 0.50±0.01 6.25±1.04 1.07±0.05 27.54±0.89 
F2 0.50±0.05 0.50±0.03 12.50±1.13 1.14±0.04 27.93±1.45 
F3 0.53±0.04 0.53±0.02 6.67±0.97 1.07±0.07 28.46±1.32 
F4 0.47±0.03 0.47±0.01 11.76±1.32 1.13±0.02 27.87±0.84 
F5 0.43±0.05 0.43±0.02 16.22±0.87 1.19±0.03 26.55±0.62 
F6 0.43±0.01 0.43±0.05 16.22±1.15 1.19±0.02 27.43±0.23 
F7 0.53±0.01 0.53±0.02 10.00±0.20 1.11±0.02 27.48±1.20 
F8 0.40±0.02 0.40±0.01 17.50±0.67 1.21±0.02 28.76±1.23 
F9 0.40±0.03 0.40±0.03 15.00±0.35 1.18±0.07 28.32±0.87 
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Table 5: Diameter, thickness, hardness and %loss in weight of formulation F1-F9 
Batch 
Code 
Diameter
* 
(mm)
 
Thickness
* 
(mm)
 
Hardness
* 
(kg/cm
2
)
 
%Loss in wt.
** 
F1 6.80±0.01 1.60±0.03 4±0.56 0.117±0.07 
F2 6.20±0.05 1.80±0.06 4.32±0.14 0.056±0.04 
F3 6.20±0.04 1.80±0.04 4.64±0.64 0.226±0.09 
F4 6.40±0.01 2.00±0.32 4.62±0.87 0.423±0.17 
F5 6.80±0.02 2.00±0.03 4.55±0.43 0.439±0.05 
F6 6.80±0.05 1.80±0.22 3.75±0.42 0.2±0.18 
F7 6.80±0.01 2.00±0.05 4.25±0.21 0.436±0.07 
F8 6.80±0.04 2.20±0.16 4.52±055 0.112±0.03 
F9 6.80±0.05 2.20±0.24 4.5±0.48 0.534±0.21 
 
Table 6: %Weight variation, disintegration time, drug content of Paracetamol and drug content of 
Metoclopramide of formulation F1-F9 
Formulation  
Code 
%Weight 
variation** 
Disintegration time 
(in sec) 
Drug content** 
of Paracetamol
 
Drug content** of 
Metoclopramide
 
F1 -0.123±1.22 105±0.02 98.256±0.005 95.319±0.020 
F2 0.235±1.56 90±0.01 96.821±0.010 97.872±0.005 
F3 0.386±0.09 110±0.04 97.867±0.006 96.596±0.008 
F4 0.256±1.24 145±0.05 96.205±0.007 99.574±0.032 
F5 0.654±1.32 134±0.01 95.385±0.006 98.298±0.004 
F6 -0.056±1.24 156±0.01 96.615±0.008 96.596±0.002 
F7 0.116±1.52 56±0.07 95.795±0.007 95.787±0.008 
F8 -0.143±0.31 62±0.01 96.615±0.017 96.340±0.003 
F9 0.237±0.03 70±0.05 96.205±0.002 97.574±0.010 
 
 
Fig. 1: Comparison graph of in vitro drug release 
profile of formulations F1-F9 containing 
Paracetamol 
 
Fig. 2: Comparison graph of in vitro drug release 
profile of formulations F1-F9 containing 
Metoclopramide hydrochloride 
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